logo-loader

Tournigan signs binding agreement to acquire Mawson's uranium properties

Last updated: 12:07 28 Dec 2011 EST, First published: 13:07 28 Dec 2011 EST

no_picture_pai

Tournigan Energy (CVE:TVC) announced Wednesday it has taken another step forward in expanding its Uranium presence in Europe, with the signing of a binding agreement to purchase seven Uranium properties in Finland and Sweden from Mawson Resources (TSE:MAW).

Under the terms of the agreement, which supersedes the letter of intent it had signed earlier this month, Tournigan will issue just under 53.64 million shares of its common stock to Mawson on a pro rata basis by April 30, 2012.

In return, Tournigan will receive Mawson's right, title, and interest in a total of seven Uranium exploration projects throughout Sweden and Finland, including the Nuottijarvi, Riutta, and Asento properties in Finland, and the Hotagen, Duobblon, Kapell, and Aronsjo properties in Sweden.

Tournigan said the deal remains subject to the conditions under the letter of intent, including the spin out of Mawson's Peruvian assets, and the overall reorganization of its business.

Separately, Tournigan has already received approval from the TSX-Venture Exchange to close a private placement financing with an affiliate of French nuclear energy powerhouse Areva SA (EPA:AREVA), one of Mawson's largest shareholders. It expects to close the private placement in early January 2012, concurrent with its entering into a technical services agreement with Areva.

The technical services agreement will see Areva conduct a work program on Tournigan's Kuriskova Uranium property, located in east-central Slovakia. The program, which will consist of metallurgical and environmental test work, will be used for a feasibility study for the property, expected for completion in early 2012.

Tournigan also said it plans to change its name to European Uranium Resources, and will complete a consolidation of its shares, on a one new for five old basis. The change will begin once the Areva alliance and Mawson acquisitions have been completed.

On distribution of the shares, Mawson shareholders shall own approximately 20.5 percent of the restructured Tournigan, which will continue as European Uranium Resources.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

15 minutes ago